Journal
ANALYTICAL CHEMISTRY
Volume 94, Issue 42, Pages 14659-14665Publisher
AMER CHEMICAL SOC
DOI: 10.1021/acs.analchem.2c02895
Keywords
-
Categories
Funding
- Spanish Research Agency (AEI) , Ministry of Science, Innovation, and Universities through the PREDICT
- CERCA Program/Generalitat de Catalunya
- Severo Ochoa Centres of Excellence program - Spanish Research Agency (AEI)
- Spanish Ministry of Science and Innovation
- Spanish Research Agency
- European Social Fund (ESF)
- Clinical and economic impact of personalized targeted anti-microRNA therapies in reconverting lung cancer chemo
- FLAG-ERA grant LEGOCHIP - Italian National Research Council
- Spanish National Research Agency
- [TEC2016-78515-R]
- [EROICA PID2019-105132RB-I00]
Ask authors/readers for more resources
This study introduces a nanophotonic biosensor for the direct and real-time detection of microRNA biomarkers related to lung cancer in human plasma. Its application in clinical samples showed competitive detectability and significance compared to traditional molecular analysis methods like qRT-PCR.
The rapid diagnosis of cancer, especially in its early stages, is crucial for on-time medical treatment and for increasing the patient survival rate. Lung cancer shows the highest mortality rate and the lowest 5-year survival rate due to the late diagnosis in advanced cancer stages. Providing rapid and reliable diagnostic tools is a top priority to address the problem of a delayed cancer diagnosis. We introduce a nanophotonic biosensor for the direct and real-time detection in human plasma of the microRNA-21-5p biomarker related to lung cancer. The biosensor employs a silicon photonic bimodal interferometric waveguide that provides a highly sensitive detection in a label-free format. We demonstrate a very competitive detectability for direct microRNA-21-5p biomarker assays in human plasma samples (estimated LOD: 25 pM). The diagnostic capability of our biosensor was validated by analyzing 40 clinical samples from healthy individuals and lung cancer patients, previously analyzed by reverse-transcription quantitative polymerase chain reaction (qRT-PCR). We could successfully identify and quantify the levels of microRNA in a one-step assay, without the need for DNA extraction or amplification steps. The study confirmed the significance of implementing this biosensor technique compared to the benchmarking molecular analysis and showed excellent agreement with previous results employing the traditional qRT-PCR. This work opens new possibilities for the true implementation of point-of-care biosensors that enable fast, simple, and efficient early diagnosis of cancer diseases.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available